Oxidative Stress and Neuroprotection [Paperback]

This book deals with basic and clinical aspects of monoamine oxidase (MAO) subtypes A and B highlighting its importance in neurological and psychiatric diseases. Consequently the therapeutic actions of MAO-A and -B inhibitors in Parkinsons disease (PK) and depression are the focus of several chapters. As MAO is the basis of the development of the oxidative stress hypothesis of PD, several chapters are devoted to iron and iron-induced oxidative stress in various experimental studies and clinical conditions. Based on these findings, new compounds have been developed which not only block MAO, but are in addition, either inhibitors of acetylcholine esterase or have iron chelating properties. The aspect of preclinical and clinical neuro protection as well as MAO neuroprotection are additional topics covered in this book. MAO, iron and neuroprotection are seen in the framework of general anti Parkinsons therapy with chapters on levodopa, dopaminergic receptor agonists and clinical issues.

Levodopa in the treatment of Parkinsons disease.- Changing dopamine agonist treatment in Parkinsons disease: experiences with switching to pramipexole.- The DONPAD-study  Treatment of dementia in patients with Parkinsons disease with donepezil.- PD-related psychosis: pathophysiology with therapeutical strategies.- Antioxidant capacity in postmortem brain tissues of Parkinsons and Alzheimers diseases.- Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines  implications for the CNS.- Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinsons disease: possible implications of glial cells.- Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.- The relationship of early studies of monoamine oxidase to present concepts.- Isatin, an endogenous MAO inhibitor, and a rat model of Parkinsons disease induced by thl>